Breaking Finance News

AbbVie (NYSE:ABBV) price target upped to $92.00, released a ratings update earlier today by UBS

Displaying a price of $87.48, AbbVie (NYSE:ABBV) traded -0.14% lower on the day. With the last close up 25.03% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. AbbVie has recorded a 50-day average of $75.76 and a two hundred day average of $69.87. Trading volume was down over the average, with 1,764,440 shares of ABBV changing hands under the typical 5,932,010

AbbVie (NYSE:ABBV) had its target price raised to $92.00 by UBS in a report issued 9/25/2017. The updated stock price target implies a potential upside of 0.05% from the company's previous close.

On 09/15/2017, Jefferies & Co released a statement for AbbVie (NYSE:ABBV) bumped up the target price from $9.00 to $10.00. At the time, this indicated a possible downside of -0.89%.

Recent Performance Chart


AbbVie has 52 week low of $55.06 and a 52 week high of $89.69 with a PE ratio of 21.49 and has a market capitalization of $0.

Also covering AbbVie's price target, a total of 18 brokerages have issued a research note on the company. The average stock price target is $70.22 with four analysts rating the company a strong buy, ten analysts rating the stock a buy, 5 firms rating the stock a hold, one equity analyst rating the company a underperform, and lastly zero brokers rating the stock a sell.

General Information About AbbVie (NYSE:ABBV)

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.